rs121912707
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM5PP3PP5_Very_Strong
The NM_001182.5(ALDH7A1):c.1279G>C(p.Glu427Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000513 in 1,613,960 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E427D) has been classified as Pathogenic.
Frequency
Genomes: 𝑓 0.00023 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00054 ( 0 hom. )
Consequence
ALDH7A1
NM_001182.5 missense
NM_001182.5 missense
Scores
9
4
1
Clinical Significance
Conservation
PhyloP100: 7.79
Genes affected
ALDH7A1 (HGNC:877): (aldehyde dehydrogenase 7 family member A1) The protein encoded by this gene is a member of subfamily 7 in the aldehyde dehydrogenase gene family. These enzymes are thought to play a major role in the detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation. This particular member has homology to a previously described protein from the green garden pea, the 26g pea turgor protein. It is also involved in lysine catabolism that is known to occur in the mitochondrial matrix. Recent reports show that this protein is found both in the cytosol and the mitochondria, and the two forms likely arise from the use of alternative translation initiation sites. An additional variant encoding a different isoform has also been found for this gene. Mutations in this gene are associated with pyridoxine-dependent epilepsy. Several related pseudogenes have also been identified. [provided by RefSeq, Jan 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
?
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 10 uncertain in NM_001182.5
PM2
?
Very rare variant in population databases, with high coverage;
PM5
?
Other missense variant is known to change same aminoacid residue: Variant chr5-126552057-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 204865.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP3
?
MetaRNN computational evidence supports a deleterious effect, 0.78
PP5
?
Variant 5-126552059-C-G is Pathogenic according to our data. Variant chr5-126552059-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 17994.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-126552059-C-G is described in Lovd as [Pathogenic]. Variant chr5-126552059-C-G is described in Lovd as [Pathogenic]. Variant chr5-126552059-C-G is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
|---|---|---|---|---|---|---|---|
| ALDH7A1 | NM_001182.5 | c.1279G>C | p.Glu427Gln | missense_variant | 14/18 | ENST00000409134.8 | |
| ALDH7A1 | NM_001201377.2 | c.1195G>C | p.Glu399Gln | missense_variant | 14/18 | ||
| ALDH7A1 | NM_001202404.2 | c.1087G>C | p.Glu363Gln | missense_variant | 12/16 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| ALDH7A1 | ENST00000409134.8 | c.1279G>C | p.Glu427Gln | missense_variant | 14/18 | 1 | NM_001182.5 | P4 |
Frequencies
GnomAD3 genomes ? AF: 0.000230 AC: 35AN: 152146Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
35
AN:
152146
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000358 AC: 90AN: 251230Hom.: 0 AF XY: 0.000361 AC XY: 49AN XY: 135782
GnomAD3 exomes
AF:
AC:
90
AN:
251230
Hom.:
AF XY:
AC XY:
49
AN XY:
135782
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000543 AC: 793AN: 1461696Hom.: 0 Cov.: 32 AF XY: 0.000532 AC XY: 387AN XY: 727150
GnomAD4 exome
AF:
AC:
793
AN:
1461696
Hom.:
Cov.:
32
AF XY:
AC XY:
387
AN XY:
727150
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000230 AC: 35AN: 152264Hom.: 0 Cov.: 32 AF XY: 0.000228 AC XY: 17AN XY: 74464
GnomAD4 genome
?
AF:
AC:
35
AN:
152264
Hom.:
Cov.:
32
AF XY:
AC XY:
17
AN XY:
74464
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
7
ExAC
?
AF:
AC:
52
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:31Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Pyridoxine-dependent epilepsy Pathogenic:25Other:1
| Pathogenic, no assertion criteria provided | clinical testing | Clinical Laboratory Sciences Program (CLSP), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) | Apr 01, 2023 | - - |
| Pathogenic, criteria provided, single submitter | research | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 17, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 14, 2023 | The ALDH7A1 c.1279G>C; p.Glu427Gln variant (rs121912707), also known as Glu399Gln for legacy nomenclature, is reported as a common pathogenic variant that has been identified both homozygous and compound heterozygous in several individuals with autosomal recessive epilepsy (Bennett 2009, Mefford 2015, Monies 2019, Schmitt 2010). Additionally, other variants at this codon (p.Glu427Asp, p.Glu427Gly) have also been reported in affected individuals (Bennett 2009). The p.Glu427Gln variant is reported in ClinVar (Variation ID: 17994). It is observed in the general population with an overall allele frequency of 0.03% (93/282634 alleles) in the Genome Aggregation Database (v2.1.1). Computational analyses predict that this variant is deleterious (REVEL: 0.944). In support of these predictions, functional analyses show an effect of this variant on enzyme activity (Coulter-Mackie 2012). Based on available information, this variant is considered to be pathogenic. References: Bennett CL et al. Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia. 2009 May;50(5):1167-75. PMID: 19128417. Coulter-Mackie MB et al. Overexpression of human antiquitin in E. coli: enzymatic characterization of twelve ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. Mol Genet Metab. 2012 Aug;106(4):478-81. PMID: 22784480. Mefford HC et al. Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. Neurology. 2015 Sep 1;85(9):756-62. PMID: 26224730. Monies D et al. Lessons Learned from Large-Scale, First-Tier Clinical Exome Sequencing in a Highly Consanguineous Population. Am J Hum Genet. 2019 Jun 6;104(6):1182-1201. PMID: 31130284. Schmitt B et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010 Jul;52(7):e133-42. PMID: 20370816. - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2007 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Courtagen Diagnostics Laboratory, Courtagen Life Sciences | Feb 20, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Feb 13, 2024 | Criteria applied: PM3_VSTR,PM5_STR,PP3 - |
| not provided, no classification provided | literature only | GeneReviews | - | The most common pathogenic variant, accounting for 33% of pathogenic variants - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 26, 2022 | The p.Glu427Gln variant in ALDH7A1 (also referred to as p.Glu399Gln in the literature) has been reported in at least 3 homozygous and 7 compound heterozygous individuals with pyridoxine-dependent epilepsy (Mills 2006 PMID: 16491085, Schmitt 2010 PMID: 20370816, Nam 2012 PMID: 22371912, Proudfoot 2012 PMID: 23430810, van Karnebeek 201 PMID: 230220702). This variant has also been identified in 45/66588 of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs121912707). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In addition, in vitro functional studies provide evidence that the p.Glu427Gln variant impacts protein function (Mills 2006 PMID: 16491085, Coulter-Mackie 2012 PMID: 22784480). In summary, this variant meets our criteria to be classified as pathogenic for pyridoxine-dependent epilepsy in an autosomal recessive manner based upon its co-occurrence with pathogenic variants in affected individuals and functional evidence. ACMG/AMP criteria applied: PM3_VeryStrong, PS3, PP3. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Dec 07, 2022 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Elsea Laboratory, Baylor College of Medicine | Apr 01, 2020 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | ALDH7A1 NM_001182.4 exon 14 p.Glu427Gln (c.1279G>C): This variant is a well known pathogenic variant and has been reported in the literature in numerous individuals with pyridoxine dependent epilepsy in the homozygous and compound heterozygous state (also reported as p.Glu399Gln; selected publications: Mills 2006 PMID:16491085, Bennett 2009 PMID:19128417, Schmitt 2010 PMID:20370816, van Karnebeek 2012 PMID:23022070, Mefford 2015 PMID:26224730, Coughlin 2019 PMID:30043187). Multiple publications suggest that this variant represents 1/3rd of mutated alleles for this gene (Bennett 2009 PMID:19128417, Mefford 2015 PMID:26224730). This variant is present in 0.04% (29/68034) of European alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/5-126552059-C-G?dataset=gnomad_r3). Please note, disease causing variants may be present in control databases at low frequencies, reflective of the general population, carrier status, and/or variable expressivity. This variant is present in ClinVar, with several labs classifying this variant as Pathogenic (Variation ID:17994). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, functional studies utilizing chinese hamster ovary cells and e.coli assays have shown a deleterious effect of this variant (Mills 2006 PMID:16491085, Coulter-Mackie 2012 PMID:22784480). Furthermore, other variants at this position (p.Glu427Gly/p.Glu399Gly and p.Glu427Asp/p.Glu399Gly) have also been reported in association with disease supporting that this codon has functional importance. In summary, this variant is classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Oct 18, 2021 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | UCLA Clinical Genomics Center, UCLA | Jun 18, 2013 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | Jan 18, 2017 | - - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jun 12, 2020 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Nov 02, 2017 | The p.Glu427Gln (commonly referred to in the literature as p.Glu399Gln) is missense variant in the ALDH7A1 gene. This variant is well reported in the literature, and had been reported to be the most prevalent pathogenic variant in ALDH7A1 (PMID: 20301659). The variant has been reported by multiple clinical laboratories as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/RCV000019610.29/). Functional studies have shown that the p.Glu427Gln results in an absence of detectable enzyme activity in a CHO in vitro cell model (PMID: 16491085). The highest reported allele frequency in the population databases is 0.0006% (81/126556 alleles). In silico modeling predicts this variant as damaging and it is highly conserved. Based on the available evidence, the p.Glu427Gln variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000017994, PMID:16491085, PS1_S). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000204865,VCV000944165, PMID:19128417,19128417, PM5_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.944, 3CNET: 0.996, PP3_P). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000329, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | Oct 08, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 25, 2017 | Across a selection of available literature, the ALDH7A1 c.1279G>C (p.Glu427Gln) missense variant, also referred to as p.Glu399Gln, has been reported in at least seven studies and identified in a total of 15 individuals, including in six in a homozygous state and in nine in a compound heterozygous state, all of whom have a diagnosis of pyridoxine-dependent epilepsy or seizures (Mills et al. 2006; Bennett et al. 2009; Schmitt et al. 2010; Nam et al. 2012; Proudfoot et al. 2013; Tlili et al. 2013; Mefford et al. 2015). The p.Glu427Gln variant was absent from 230 controls but is reported at a frequency of 0.00081 in the European American population of the Exome Sequencing Project. Functional studies using transfected CHO cells were performed by Mills et al. (2006) and found α-AASA dehydrogenase activity to be undetectable. Coulter-Mackie et al. (2012) used transfected E. coli and observed enzyme activity levels below the level of detection for the assay. Based on the collective evidence, the p.Glu427Gln variant is classified as pathogenic for pyridoxine-dependent epilepsy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 30, 2022 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with pyridoxine-dependent epilepsy (MIM#266100). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glutamic acid to glutamine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (93 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (1 heterozygote, 0 homozygotes). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated NAD binding site within the aldehyde dehydrogenase domain (NCBI, DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic and likely pathogenic, and is described as the most common pathogenic variant among European patients (ClinVar, PMID: 30043187). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
| Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Sep 23, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 31, 2024 | This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 427 of the ALDH7A1 protein (p.Glu427Gln). This variant is present in population databases (rs121912707, gnomAD 0.06%). This missense change has been observed in individual(s) with pyridoxine dependent epilepsy (PMID: 16491085, 19128417, 22371912, 26224730). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 17994). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALDH7A1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ALDH7A1 function (PMID: 16491085). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 03, 2022 | Published functional studies demonstrate the variant abolishes enzyme activity (Mills et al., 2006; Coulter-Mackie et al., 2012); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31652343, 16491085, 26555630, 17068770, 17088338, 17721876, 26224730, 29056246, 31164858, 31980526, 20370816, 22371912, 22784480, 27438048, 26995068, 26943461, 16159904, 28832562, 29453417, 30609409, 29401530, 31737911, 31564432, 23430810, 30043187, 31130284, 23022070, 31589614, 34426522, 32685344) - |
| Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 23, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jun 28, 2017 | - - |
Pyridoxine-dependent epilepsy caused by ALDH7A1 mutant Pathogenic:1
| Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | May 04, 2022 | The homozygous p.Glu427Gln variant in ALDH7A1 was identified by our study in 1 individual with pyridoxine-dependent epilepsy. The variant has been reported in at least 10 individuals of European and unknown ethnicity with pyridoxine-dependent epilepsy (PMID: 16491085, 19128417), and has been identified in 0.06% (79/129032) of European non-Finnish, 0.02% (4/19918) of East Asian, and 0.01% (4/35418) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs121912707). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 17994) as pathogenic by multiple submitters and as likely pathogenic by UCLA Clinical Genomics Center. In vitro functional studies provide some evidence that the p.Glu427Gln variant may impact protein function (PMID: 22784480, 16491085). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The presence of this variant in at least 5 affected homozygotes, and in combination with 2 reported pathogenic variants, and in at least 10 individuals with pyridoxine-dependent epilepsy increases the likelihood that the p.Glu427Gln variant is pathogenic (VariationID: 17995, 204852; PMID: 16491085, 19128417). The p.Glu427Gln variant is located in a region of ALDH7A1 that is essential to protein folding and stability, suggesting that this variant is in a mutational hotspot and slightly supports pathogenicity (PMID: 16491085, 31652343). One additional likely pathogenic variants, resulting in a different amino acid change at the same position (p.Glu427Gly), have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 19128417). In summary, the p.Glu427Gln variant is pathogenic based off of our findings of multiple reports in ClinVar, and the literature. ACMG/AMP Criteria applied: PM3_strong, PM5_supporting, PM1, PS3_moderate, PP3 (Richards 2015). - |
Seizure Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 13, 2014 | The p.E427Q pathogenic mutation (also known as c.1279G>C), located in coding exon 14 of the ALDH7A1 gene, results from a G to C substitution at nucleotide position 1279. The glutamic acid at codon 427 is replaced by glutamine, an amino acid with highly similar properties. This mutation has been described in numerous unrelated individuals with pyroxidine-dependent seizures in both homozygous and compound heterozygous states, and is reported to be the most common ALDH7A1 mutation, accounting for approximately 30% of mutant alleles (Mills PB et al. Nat. Med., 2006 Mar;12:307-9; Plecko B et al. Hum. Mutat., 2007 Jan;28:19-26; Bennett CL et al. Epilepsia, 2009 May;50:1167-75; Nam SH et al. Ann. Clin. Lab. Sci., 2012;42:65-72; Mefford HC et al. Neurology, 2015 Sep;85:756-62; Butler KM et al.<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px"> Pediatr. Neurol.<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px">, 2017 Dec;77:61-66<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px">). Enzyme activity in transfected CHO cells and E. coli cells have demonstrated undetectable or extremely low (<3% of WT) enzyme activity (Mills PB et al. Nat. Med., 2006 Mar;12:307-9; Coulter-Mackie MB et al. Mol. Genet. Metab., 2012 Aug;106:478-81). <span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px">In addition, this alteration is predicted to be probably damaging, deleterious, and deleterious by PolyPhen and<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px"> SIFT<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px"> in silico<span style="background-color:rgb(255, 255, 255); color:rgb(51, 51, 51); font-family:sans-serif,arial,verdana,trebuchet ms; font-size:13px"> analyses, respectively.Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
T;D;T;.;T;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationTaster
Benign
A;A;A
PrimateAI
Uncertain
T
Polyphen
1.0
.;D;.;.;.;.;.;.
Vest4
0.94, 0.93
MVP
0.99
MPC
0.60
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at